Q-omics provides the consensus-scored LINC01574 profile across patient tissues and cancer cell-line models. LINC01574 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, LINC01574 is differentially expressed in 7, with the highest sampling consensus in UCEC. Additionally, LINC01574 RNA expression shows 9,363 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, UCEC, and TGCT as cancer lineages where LINC01574 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01574 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01574 survival associations across molecular data types. LINC01574 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01574 RNA expression–survival associations across cancer types. High LINC01574 expression shows unfavorable associations in BRCA, UCEC, STAD, SKCM, KIRC and LUAD. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for LINC01574 RNA expression.
This table summarizes LINC01574 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01574. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01574 shows lower tumor expression in UCEC and THCA and higher tumor expression in BRCA, LUSC, LUAD and KIRP. The UCEC box plot shows higher LINC01574 RNA expression in normal versus tumor tissue (log2 FC = −0.865, t-test p < 0.001).
This table shows molecular features associated with LINC01574 in patient tissues and cancer cell lines. In patient samples, LINC01574 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
